A microorganism that haunted archaeologists for a century has become a source of hope.
From the sealed chambers of ancient tombs to the laboratories of modern medicine, a fungus long feared as an instrument of death is being reimagined as a healer. Researchers at the University of Pennsylvania have transformed Aspergillus flavus — the microorganism implicated in the deaths of archaeologists who disturbed Tutankhamun's burial chamber — into an engineered compound that selectively destroys leukemia cells while sparing healthy tissue. The discovery invites us to consider how often the boundary between poison and cure is not fixed, but waiting to be redrawn by human ingenuity and curiosity.
- A fungus blamed for killing ten of twelve archaeologists who entered a Polish royal tomb in 1970 has now been redirected toward fighting cancer in laboratory experiments.
- The engineered molecules, called asperigimicinas, can identify and destroy leukemia cells with surgical precision — a stark contrast to the broad cellular damage caused by conventional chemotherapy.
- Their stability as cyclic peptides allows them to resist breaking down inside the body, giving them the durability needed to act as targeted therapeutic agents.
- Lead researcher Sherry Gao warns that this is only the beginning — similar gene clusters likely exist across many fungal species, suggesting a vast pharmaceutical frontier that science has barely entered.
- Animal testing is the immediate next step, with human clinical trials on the horizon if early results continue to hold, keeping cautious optimism in careful check.
When Howard Carter's team unsealed Tutankhamun's burial chamber in 1922, team members began dying in ways that defied easy explanation. For decades the cause was attributed to a vague curse. Science eventually identified the true culprit: ancient spores of Aspergillus flavus, a fungus capable of triggering fatal lung infections, especially in those with compromised immunity. The pattern repeated in 1970, when ten of twelve archaeologists who entered the tomb of Polish king Casimiro IV died within weeks of the same infection.
Now researchers at the University of Pennsylvania have taken this historically deadly microorganism and engineered it into something entirely different. By modifying specific genes within the fungus, they prompted it to produce molecules called asperigimicinas — cyclic peptides with a compact, stable structure that allows them to resist degradation inside the body and strike cancer cells with precision. In laboratory tests, these compounds successfully eliminated leukemia cells while leaving healthy tissue unharmed, suggesting a therapeutic approach far less toxic than current chemotherapy.
The molecules work by recognizing specific structures on malignant cells and disabling them from within, generated through a ribosomal synthesis process that also enhances their cancer-fighting properties. Lead researcher Sherry Gao draws a direct line from this discovery to one of medicine's most celebrated breakthroughs: fungi gave us penicillin, she notes, and the natural world still holds many more pharmaceutical secrets. Her team's findings, published in Nature Chemical Biology, point toward similar gene clusters in other fungal species — an entire unexplored territory of potential treatments.
First author Qiuyue Nie underscores how much remains unknown, and how promising that unknown appears: nearly every fungal compound identified so far has shown strong biological activity. Animal testing is the next phase, with human clinical trials to follow if those results hold. What the work ultimately represents is a profound reversal — a microorganism wrapped for a century in the language of curses and death, now being carefully shaped into an instrument of healing.
A fungus that killed archaeologists opening ancient tombs may soon save cancer patients. Researchers at the University of Pennsylvania have engineered a deadly strain of Aspergillus flavus—the microorganism long blamed for the deaths of excavators who disturbed Tutankhamun's burial chamber in 1922—into a precision weapon against leukemia and other blood cancers.
The story begins with mystery and death. When Howard Carter's team unsealed the pharaoh's tomb nearly a century ago, team members began dying unexpectedly. For decades, the cause remained unclear, attributed to a vague "curse." But scientists eventually identified the culprit: ancient spores of Aspergillus flavus, a fungus that can trigger severe lung infections, particularly in people with weakened immune systems. The pattern repeated in 1970 when archaeologists entered the tomb of Polish king Casimiro IV. Within weeks, ten of the twelve expedition members were dead from the same fungal infection.
Now researchers have taken this killer and transformed it. By modifying specific genes in the fungus, they coaxed it to produce molecules called asperigimicinas—compounds that can identify cancer cells and destroy them from within while leaving healthy tissue untouched. In laboratory tests, these engineered molecules successfully eliminated leukemia cells without damaging surrounding cells, suggesting a treatment far more precise and less toxic than current chemotherapy approaches.
The mechanism is elegant. Asperigimicinas are cyclic peptides, meaning they have a stable, compact shape that allows them to resist breaking down in the body and strike with surgical accuracy. They recognize specific structures on malignant cells and disable them. The molecules are produced through a process called ribosomal synthesis, where the cell's protein-making machinery generates the compound and then modifies it to enhance its cancer-fighting power.
Sherry Gao, the lead researcher and presidential associate professor of chemical and biomolecular engineering at Penn, frames the discovery within a larger pattern. "Fungi gave us penicillin," she notes. "These results show there are still many more drugs from natural products waiting to be discovered." Her team's findings, published in Nature Chemical Biology, suggest that similar gene clusters exist in other fungal species, pointing toward an entire unexplored pharmaceutical frontier.
Qiuyue Nie, the paper's first author, emphasizes the scale of what remains unknown. Though only a handful of these fungal compounds have been identified so far, nearly all show strong biological activity. "This is an unexplored region with enormous potential," she says. The next phase involves testing asperigimicinas in animal models, with human clinical trials potentially following if those results hold promise.
What makes this work remarkable is not just the science but the reversal it represents. A microorganism that haunted archaeologists for a century—blamed for sudden deaths, wrapped in the language of curses and supernatural punishment—has become a source of hope. The same spores that once killed are now being engineered to kill cancer instead. Gao captures the philosophical shift in her closing thought: "Nature has given us this incredible pharmacy. It's up to us to reveal its secrets."
Notable Quotes
Fungi gave us penicillin. These results show there are still many more drugs from natural products waiting to be discovered.— Sherry Gao, lead researcher, University of Pennsylvania
This is an unexplored region with enormous potential.— Qiuyue Nie, first author of the study
The Hearth Conversation Another angle on the story
How did researchers decide to look at this particular fungus for cancer treatment? It seems like an odd starting point.
It wasn't random. Scientists had already identified Aspergillus flavus as the cause of those archaeologist deaths, so they understood its biology well. Once you know a microorganism intimately—how it grows, what it produces—you can start asking whether any of its natural compounds might be useful. The fungus was already being studied. The leap was asking: what if we engineered it differently?
But the fungus kills people. How is that safe to work with in a lab?
That's the whole point of the genetic modification. They didn't use the dangerous form. They altered the genes to change what the fungus produces. The asperigimicinas are new molecules—they don't exist in nature. The fungus becomes a factory for something entirely different from what made it lethal.
The article mentions these are cyclic peptides. Why does that shape matter so much?
Shape determines function in biology. A cyclic peptide is like a closed loop—compact and stable. It can survive longer in the body without breaking down, and that stability lets it find and hit its target with precision. A fragile molecule would fall apart before reaching the cancer cells.
So we're still years away from this being a treatment people can actually receive?
Yes. They've shown it works in the lab on cancer cells. Next comes animal testing to see if it works in living systems and doesn't cause unexpected harm. Only after that would come human trials. That's typically a years-long process. But the early results are genuinely promising—they killed leukemia cells without touching healthy tissue.
What's the broader implication here? Is this about fungi specifically, or something larger?
Both. The researchers found similar gene clusters in other fungi, suggesting there are dozens or hundreds of undiscovered compounds out there. We've barely scratched the surface of what fungi can produce. This work is saying: stop looking only at obvious places for new drugs. Nature has been making complex molecules for millions of years. We're just learning to read the instructions.